000278782 001__ 278782
000278782 005__ 20250604100729.0
000278782 0247_ $$2doi$$a10.1002/alz.14307
000278782 0247_ $$2pmid$$apmid:39985404
000278782 0247_ $$2pmc$$apmc:PMC12079645
000278782 0247_ $$2ISSN$$a1552-5260
000278782 0247_ $$2ISSN$$a1552-5279
000278782 037__ $$aDZNE-2025-00618
000278782 041__ $$aEnglish
000278782 082__ $$a610
000278782 1001_ $$0P:(DE-2719)9002169$$aKuhn, Elizabeth$$b0$$eFirst author
000278782 245__ $$aSCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies.
000278782 260__ $$aHoboken, NJ$$bWiley$$c2025
000278782 3367_ $$2DRIVER$$aarticle
000278782 3367_ $$2DataCite$$aOutput Types/Journal article
000278782 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748937983_11720
000278782 3367_ $$2BibTeX$$aARTICLE
000278782 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278782 3367_ $$00$$2EndNote$$aJournal Article
000278782 520__ $$aSpecific features of subjective cognitive decline (SCD-plus) have been proposed to indicate an increased risk of preclinical Alzheimer's disease (AD). However, few studies have examined how these features relate to AD biomarkers in cognitively unimpaired (CU) older adults.Meta-analyses were performed using cross-sectional data from nine cohorts (n = 7219, mean age (SD): 71.17 (5.9), 56.5% female) to determine associations of SCD-plus features with positron emission tomography (PET)- or cerebrospinal fluid (CSF)-derived amyloid beta (Aβ) and tau biomarkers.Participants with preclinical AD (community-based only) were more likely to fulfill SCD-plus features. The presence of self-reported memory decline, associated concern/worry, and a higher number of fulfilled features were all associated with high Aβ levels. Only the latter was associated with abnormal tau.Simultaneous endorsement of multiple SCD-plus features is a robust indicator of abnormal AD biomarkers in CU older adults, whereas isolated SCD features seem only sensitive to elevated Aβ, supporting their value as early behavioral markers of preclinical AD.About two-tenths of our sample had abnormal amyloid beta (Aβ) levels with evidence of subjective cognitive decline (SCD). Preclinical AD subsamples (community-based) had a higher percentage of participants meeting SCD-plus features. Self-reported memory decline and concern/worry were the sole features associated with high Aβ, but not tau, burden. A higher number of fulfilled SCD-plus features are linked to high Aβ and tau burden. Use of multiple SCD-plus features may help identify early stages of biological AD.
000278782 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278782 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278782 650_7 $$2Other$$aAlzheimer's disease
000278782 650_7 $$2Other$$aSCD‐Initiative
000278782 650_7 $$2Other$$aamyloid pathology
000278782 650_7 $$2Other$$acerebrospinal fluid
000278782 650_7 $$2Other$$ameta‐analysis
000278782 650_7 $$2Other$$apositron emission tomography
000278782 650_7 $$2Other$$asubjective cognitive decline
000278782 650_7 $$2Other$$atau burden
000278782 650_7 $$2NLM Chemicals$$aBiomarkers
000278782 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000278782 650_7 $$2NLM Chemicals$$atau Proteins
000278782 650_2 $$2MeSH$$aHumans
000278782 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000278782 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000278782 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000278782 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000278782 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000278782 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000278782 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000278782 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000278782 650_2 $$2MeSH$$aPositron-Emission Tomography
000278782 650_2 $$2MeSH$$aFemale
000278782 650_2 $$2MeSH$$aMale
000278782 650_2 $$2MeSH$$aAged
000278782 650_2 $$2MeSH$$aCohort Studies
000278782 650_2 $$2MeSH$$aCross-Sectional Studies
000278782 693__ $$0EXP:(DE-2719)DELCODE-20140101$$5EXP:(DE-2719)DELCODE-20140101$$eLongitudinal Cognitive Impairment and Dementia Study$$x0
000278782 7001_ $$00009-0006-5633-2954$$aKlinger, Hannah M$$b1
000278782 7001_ $$aAmariglio, Rebecca E$$b2
000278782 7001_ $$0P:(DE-2719)2000057$$aWagner, Michael$$b3$$udzne
000278782 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b4$$udzne
000278782 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b5$$udzne
000278782 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael T$$b6
000278782 7001_ $$00000-0002-4889-7932$$aChételat, Gael$$b7
000278782 7001_ $$aRentz, Dorene M$$b8
000278782 7001_ $$aSperling, Reisa A$$b9
000278782 7001_ $$aEbenau, Jarith L$$b10
000278782 7001_ $$aButterbrod, Elke$$b11
000278782 7001_ $$00000-0001-8766-6224$$aVan Der Flier, Wiesje M$$b12
000278782 7001_ $$aSikkes, Sietske A M$$b13
000278782 7001_ $$00000-0002-4061-0837$$aTeunnissen, Charlotte E$$b14
000278782 7001_ $$00000-0002-1477-8724$$aVan Harten, Argonde C$$b15
000278782 7001_ $$00000-0001-9956-4233$$aVan De Giessen, Elsmarieke M$$b16
000278782 7001_ $$00000-0002-7411-1921$$aRami, Lorena$$b17
000278782 7001_ $$00000-0002-5646-0482$$aTort, Adria$$b18
000278782 7001_ $$00000-0003-3454-800X$$aSánchez Benavides, Gonzalo$$b19
000278782 7001_ $$00000-0001-6232-9408$$aGifford, Katherine A$$b20
000278782 7001_ $$aVan Hulle, Carol$$b21
000278782 7001_ $$00000-0002-5356-5537$$aBuckley, Rachel F$$b22
000278782 7001_ $$aInitiative, Alzheimer's Disease Neuroimaging$$b23$$eCollaboration Author
000278782 7001_ $$aBiomarkers, Australian Imaging$$b24
000278782 7001_ $$aLifestyle flagship study of ageing, A4 Study Team$$b25$$eCollaboration Author
000278782 7001_ $$aStudy, DELCODE$$b26$$eCollaboration Author
000278782 7001_ $$aStudy, Harvard Aging Brain$$b27$$eCollaboration Author
000278782 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b28$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2811351$$aBürger, Katharina$$b29$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2000055$$aLaske, Christoph$$b30$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b31$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b32$$eContributor$$udzne
000278782 7001_ $$aPriller, Joseph$$b33$$eContributor
000278782 7001_ $$0P:(DE-2719)2812825$$aRamirez, Alfredo$$b34$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2812035$$aSchneider, Anja$$b35$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b36$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b37$$eContributor$$udzne
000278782 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b38$$eContributor$$udzne
000278782 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.14307$$gVol. 21, no. 5, p. e14307$$n5$$pe14307$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.docx
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.docx
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP3.pdf
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618.pdf$$yOpenAccess
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.doc
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.odt
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.pdf
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.doc
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.odt
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.pdf
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP3.pdf?subformat=pdfa$$xpdfa
000278782 8564_ $$uhttps://pub.dzne.de/record/278782/files/DZNE-2025-00618.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000278782 909CO $$ooai:pub.dzne.de:278782$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000278782 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002169$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000278782 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000057$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000278782 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000278782 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810593$$aExternal Institute$$b28$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811351$$aExternal Institute$$b29$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000055$$aExternal Institute$$b30$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812234$$aExternal Institute$$b31$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811024$$aExternal Institute$$b32$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812825$$aExternal Institute$$b34$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812035$$aExternal Institute$$b35$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811324$$aExternal Institute$$b36$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000026$$aExternal Institute$$b37$$kExtern
000278782 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811317$$aExternal Institute$$b38$$kExtern
000278782 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278782 9141_ $$y2025
000278782 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000278782 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000278782 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000278782 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000278782 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000278782 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000278782 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000278782 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000278782 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000278782 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000278782 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000278782 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000278782 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x0
000278782 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x1
000278782 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x2
000278782 980__ $$ajournal
000278782 980__ $$aVDB
000278782 980__ $$aUNRESTRICTED
000278782 980__ $$aI:(DE-2719)1011201
000278782 980__ $$aI:(DE-2719)1011102
000278782 980__ $$aI:(DE-2719)5000006
000278782 9801_ $$aFullTexts